Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD 2: Peginesatide vs Epoetin for Anemia in Hemodialysis
NCT00597584Phase 3Completed
- Sponsor
- Affymax, Inc.
- Start
- Oct 2007
- Primary completion
- Jul 2009
- Modality
- Peptides, Polymer-based Nanoparticles
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of peginesatide in anemia (2 arms), sponsored by Affymax, Inc. Primary endpoint: Mean Change in Hemoglobin Between Baseline and the Evaluation Period. Started Oct 2007; status: completed.
02
Drugs
peginesatide
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00597584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597584.